La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

H.U. Group Holdings Crescita futura

Future criteri di controllo 3/6

H.U. Group Holdings prevede che gli utili e i ricavi cresceranno rispettivamente di 70.8% e 3.3% all'anno. Si prevede che l'EPS crescerà di 70.7% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 5.5% in 3 anni.

Informazioni chiave

70.8%

Tasso di crescita degli utili

70.7%

Tasso di crescita dell'EPS

Healthcare crescita degli utili	9.6%
Tasso di crescita dei ricavi	3.3%
Rendimento futuro del capitale proprio	5.5%
Copertura analitica	Good
Ultimo aggiornamento	08 Aug 2024

Aggiornamenti recenti sulla crescita futura

Analysts Have Been Trimming Their H.U. Group Holdings, Inc. (TSE:4544) Price Target After Its Latest Report

Jun 24

Recent updates

Analysts Have Been Trimming Their H.U. Group Holdings, Inc. (TSE:4544) Price Target After Its Latest Report

Jun 24

Does H.U. Group Holdings (TSE:4544) Have A Healthy Balance Sheet?

Jun 21

H.U. Group Holdings, Inc.'s (TSE:4544) Intrinsic Value Is Potentially 54% Above Its Share Price

Feb 28

Previsioni di crescita degli utili e dei ricavi

TSE:4544 - Stime future degli analisti e dati finanziari passati (JPY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	259,884	7,377	13,766	22,398	6
3/31/2026	250,916	5,137	12,921	21,838	6
3/31/2025	242,208	3,611	12,676	23,623	6
3/31/2024	236,950	-7,553	-1,006	16,551	N/A
12/31/2023	237,456	-6,458	7,264	22,725	N/A
9/30/2023	243,370	-1,699	4,485	22,297	N/A
6/30/2023	252,197	8,969	1,162	20,243	N/A
3/31/2023	260,908	15,676	10,849	32,535	N/A
12/31/2022	276,026	22,870	7,113	36,048	N/A
9/30/2022	273,286	25,633	20,412	50,133	N/A
6/30/2022	274,783	26,843	22,139	55,675	N/A
3/31/2022	272,944	29,599	20,104	55,229	N/A
12/31/2021	259,808	30,266	24,279	54,007	N/A
9/30/2021	258,189	31,885	18,863	46,670	N/A
6/30/2021	242,604	27,194	23,061	47,458	N/A
3/31/2021	223,016	17,468	14,400	35,588	N/A
12/31/2020	207,955	9,077	9,573	27,221	N/A
9/30/2020	193,798	2,042	2,379	20,128	N/A
6/30/2020	186,332	-3,054	-9,004	7,478	N/A
3/31/2020	188,712	-516	-336	15,229	N/A
12/31/2019	188,014	2,733	251	15,923	N/A
9/30/2019	185,231	4,457	-6,158	10,301	N/A
6/30/2019	182,727	5,697	-5,853	14,890	N/A
3/31/2019	181,415	6,386	-10,465	16,244	N/A
12/31/2018	178,473	886	-19,173	11,332	N/A
9/30/2018	181,159	9,801	-13,180	16,227	N/A
6/30/2018	188,204	-2,499	-9,105	16,038	N/A
3/31/2018	195,400	257	-1,527	15,767	N/A
12/31/2017	202,563	6,272	N/A	21,755	N/A
9/30/2017	205,497	359	N/A	27,058	N/A
6/30/2017	204,346	2,948	N/A	30,600	N/A
3/31/2017	204,245	333	N/A	36,436	N/A
12/31/2016	206,217	5,091	N/A	35,250	N/A
9/30/2016	208,413	-16,703	N/A	33,322	N/A
6/30/2016	211,076	-7,065	N/A	34,120	N/A
3/31/2016	211,743	-5,081	N/A	29,316	N/A
12/31/2015	209,940	-7,471	N/A	31,432	N/A
9/30/2015	208,432	14,365	N/A	30,324	N/A
6/30/2015	206,193	16,713	N/A	31,320	N/A
3/31/2015	204,667	16,002	N/A	29,261	N/A
12/31/2014	204,911	16,454	N/A	27,867	N/A
9/30/2014	204,342	14,813	N/A	28,711	N/A
6/30/2014	203,997	14,350	N/A	28,080	N/A
3/31/2014	203,371	15,322	N/A	28,723	N/A
12/31/2013	200,277	15,391	N/A	29,857	N/A
9/30/2013	197,123	15,412	N/A	31,189	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che 4544 diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 0.3% ).

Guadagni vs Mercato: Si prevede che 4544 diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede 4544 diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 4544 ( 3.3% all'anno) crescerà più lentamente rispetto al mercato JP ( 4.3% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 4544 ( 3.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 4544 sarà basso tra 3 anni ( 5.5 %).

H.U. Group Holdings Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 8.1% to JP¥2,314

Analysts Have Been Trimming Their H.U. Group Holdings, Inc. (TSE:4544) Price Target After Its Latest Report

H.U. Group Holdings, Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Consensus EPS estimates fall by 30%

Price target decreased by 9.4% to JP¥2,727

Consensus EPS estimates increase by 17%

Recent updates

H.U. Group Holdings (TSE:4544) Is Due To Pay A Dividend Of ¥62.00

Estimating The Fair Value Of H.U. Group Holdings, Inc. (TSE:4544)

Now 25% undervalued

Price target decreased by 8.1% to JP¥2,314

H.U. Group Holdings, Inc. and Fujirebio Launches the Fully Automated Lumipulse G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu

H.U. Group Holdings (TSE:4544) Is Paying Out A Dividend Of ¥62.00

H.U. Group Holdings' (TSE:4544) Dividend Will Be ¥62.00

Final dividend of JP¥62.00 announced

H.U. Group Holdings, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Analysts Have Been Trimming Their H.U. Group Holdings, Inc. (TSE:4544) Price Target After Its Latest Report

Full year 2024 earnings: EPS misses analyst expectations

Does H.U. Group Holdings (TSE:4544) Have A Healthy Balance Sheet?

Full year 2024 earnings: EPS misses analyst expectations

H.U. Group Holdings, Inc., Annual General Meeting, Jun 18, 2024

Now 21% undervalued after recent price drop

H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Chief Financial Officer

H.U. Group Holdings, Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Upcoming dividend of JP¥63.00 per share

H.U. Group Holdings, Inc.'s (TSE:4544) Intrinsic Value Is Potentially 54% Above Its Share Price

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

H.U. Group Holdings, Inc. to Report Q3, 2024 Results on Feb 09, 2024

H.U. Group Holdings Inc. and Fujirebio Announces the Availability of the Lumipulse G pTau 217 Plasma Assay for the Fully Automated LUMIPULSE G Immunoassay Systems

H.U. Group Holdings, Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 30%

Price target decreased by 9.4% to JP¥2,727

Upcoming dividend of JP¥62.00 per share at 4.7% yield

H.U. Group Holdings, Inc.(TSE:4544) dropped from FTSE All-World Index (USD)

H.U. Group Holdings, Inc.(TSE:4544) dropped from FTSE All-World Index (USD)

H.U. Group Holdings, Inc. to Report Q2, 2024 Results on Nov 09, 2023

Consensus EPS estimates increase by 17%

First quarter 2024 earnings released: JP¥19.66 loss per share (vs JP¥98.23 profit in 1Q 2023)

Now 20% undervalued after recent price drop

H.U. Group Holdings, Inc. to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings: EPS misses analyst expectations

H.U. Group Holdings, Inc. Announces Dividend for the Year Ended March 31, 2023, Payable on May 30, 2023; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024

Full year 2023 earnings: EPS misses analyst expectations

H.U. Group Holdings, Inc., Annual General Meeting, Jun 20, 2023

Upcoming dividend of JP¥63.00 per share at 4.7% yield

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: JP¥56.86 (vs JP¥105 in 3Q 2022)

H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2023

H.U. Group Holdings, Inc. to Report Q3, 2023 Results on Feb 08, 2023

Second quarter 2023 earnings released: EPS: JP¥175 (vs JP¥196 in 2Q 2022)

Second quarter 2023 earnings released: EPS: JP¥175 (vs JP¥196 in 2Q 2022)

Upcoming dividend of JP¥62.00 per share

H.U. Group Holdings, Inc. to Report Q2, 2023 Results on Nov 09, 2022

Consensus forecasts updated

H.U. Group Holdings, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

First quarter 2023 earnings released: EPS: JP¥98.23 (vs JP¥146 in 1Q 2022)

Now 20% undervalued

Price target decreased to JP¥3,137

Now 21% undervalued

Full year 2022 earnings: Revenues exceed analyst expectations

Price target decreased to JP¥3,055

Now 20% undervalued after recent price drop

H.U. Group Holdings, Inc. to Report Q1, 2023 Results on Aug 09, 2022

Consensus EPS estimates increase by 27%

H.U. Group Holdings, Inc. Provides Dividend Guidance for the Fiscal Year Ended March 31, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

H.U. Group Holdings, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

H.U. Group Holdings, Inc. Announces Board Changes

H.U. Group Holdings, Inc. to Report Fiscal Year 2022 Results on May 12, 2022

H.U. Group Holdings, Inc. Announces Launch of Fully Automated Lumipulse G ß-Amyloid 1-42 and ß-Amyloid 1-40 Plasma Assays for Research Use Only

Upcoming dividend of JP¥63.00 per share

Fujirebio Enters the Field of Fully Automated Blood-Based Alzheimer’s Disease Biomarker Testing with the Release of the Lumipulse® G Ptau 181 Plasma Assay for Research Use Only

Consensus EPS estimates increase by 11%